TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed multiple myeloma requiring treatment~  * Smoldering myeloma with evidence of progressive disease requiring chemotherapy~    * More than 25% increase in M component levels and/or Bence-Jones excretion or symptom development~ * Non-secretory patients with at least 30% bone marrow plasmacytosis~* No IgM peaks unless there is evidence of more than 30% bone marrow plasmacytosis or more than 3 lytic lesions~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* Zubrod 0-2 OR~* Zubrod 3-4 based solely on bone pain~Life expectancy~* Not specified~Hematopoietic~* No untreated, unresolved symptomatic hyperviscosity~Hepatic~* Hepatitis B negative~Renal~* Creatinine no greater than 3 mg/dL if in renal failure and on dialysis (after hydration and/or correction of hypercalcemia)~Cardiovascular~* No history of chronic cerebrovascular accident~* No myocardial infarction within the past 6 months~* No unstable angina~* No congestive heart failure that is difficult to control~* No uncontrollable hypertension~* No cardiac arrhythmia that is difficult to control~Pulmonary~* No history of chronic obstructive or chronic restrictive pulmonary disease~* No untreated, unresolved pneumonia~* Pulmonary function tests (PFTs) at least 50% of predicted~* DLCO at least 50% of predicted~* Arterial partial pressure of oxygen greater than 70 if unable to complete PFTs due to bone pain or fracture~Other~* HIV negative~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No untreated, unresolved pathologic fractures~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use at least 2 highly effective methods of contraception for 4 weeks before, during, and for at least 4 weeks after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No more than 8 weeks of prior thalidomide therapy~Chemotherapy~* No prior chemotherapy for this disease~Endocrine therapy~* Prior steroid therapy allowed provided treatment duration was no more than 2 weeks~Radiotherapy~* No prior radiotherapy to more than 50% of the pelvis~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intensive care patients scheduled for continuous venovenous hemofiltration~Exclusion Criteria:~* Severe pre-existent liver failure (cirrhosis Child C), acute liver dysfunction as occurring with septic shock is not a reason for exclusion~* Active bleeding or bleeding necessitating the infusion of two red blood cell units within 24 hours before starting hemofiltration or a fall in hemoglobin of \> 0.5 mmol/l. A fall in hemoglobin/hematocrit as a result of fluid loading is not regarded as bleeding.~* Surgery within 24 h prior to CVVH.~* Patients needing full systemic anticoagulation (unfractionated heparin in a dose of \> 10000 IU/day, or nadroparin \> 3800 IU/day) for other reasons~* Expectation to die within 24 hours~* Chronic dialysis~* Proven or suspected heparin-induced thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- citrate (Type: ACTIVE_COMPARATOR): regional anticoagulation with citrate
- nadroparin (Type: ACTIVE_COMPARATOR): nadroparin is a low molecular weight heparin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol for Catheter Related Bladder Discomfort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age,~* American Society of Anesthesiologists (ASA) Physical Status of I-II,~* undergoing PNL with urinary bladder catheter.~Exclusion Criteria:~* obesity (BMI \> 30),~* chronic opioid use,~* bladder outflow obstruction,~* benign prostatic hyperplasia, and~* overactive bladder (OAB) (frequency \> 3 times at night or \> 8 times within 24h).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl (Type: PLACEBO_COMPARATOR): None
- Group Paracetamol(n=32):iv 15mg/kg paracetamol (Type: ACTIVE_COMPARATOR): The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was \>3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Age ≥ 75 or age 65-74 with at least 1 of the following comorbidities: arterial hypertension, diabetes, obesity, chronic obstructive pulmonary disease, heart disease, chronic kidney disease~* Last 48 hours: (A)Axillary temperature ≥ 37.5oC or febrile equivalent, combined with (a) dry cough and/or (b) breathing difficulty and/or (c) odinophagia and/or (d) anosmia/dysgeusia and/or (e) any of the following symptoms: fatigue, anorexia, myalgias or rhinorrhea.~* Confirmed diagnosis SARS-Cov2 by RT-PCR~* Give Informed consent~Exclusion Criteria:~* Severe respiratory disease~* Cardiac insufficiency,~* Chronic renal failure,~* Primary hypogammaglobulinemias,~* Myelodysplastic syndromes,~* Chronic linfoproliferative syndromes,~* Monoclonal gammapathies,~* Known hypersensitibility,~* Active cancer,~* HIV, HBV or HCV infection,~* Chronic administration of immunosuppressants,~* Body transplant history,~* Chronic liver disease, Chronic lung disease with oxygen requirement.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasma (Type: EXPERIMENTAL): Convalescent plasma with an IgG titer against SARS-CoV2
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria:~* Histologic documentation of one of the following: breast adenocarcinoma, prostate adenocarcinoma or multiple myeloma~* At least one site of bone metastasis or bone involvement by radiologic imaging including plain radiograph, computed tomography (CT), positron emission tomography (PET) scan, PET/CT scan, magnetic resonance imaging, bone scan, or skeletal survey; indeterminate lesions should be confirmed by a second imaging method~* No prior treatment with IV bisphosphonates is allowed; prior treatment with oral bisphosphonates is allowed, but they must be discontinued prior to the initiation of protocol therapy~* No prior treatment with denosumab~* No prior treatment with radiopharmaceuticals; prior treatment with radioactive iodine is allowed; prostate cancer patients treated with brachytherapy are eligible~* Prior radiation therapy to bone is allowed, provided that at least one site of bone metastasis has not been irradiated and radiation is completed prior to registration; there should be no plan for radiation therapy to non-irradiated sites of bone metastases~* Prior adjuvant and metastatic chemotherapy, biologic therapy, and endocrine therapy is allowed~* No current treatment with investigational agent(s)~* Patients with known brain metastases are not eligible; patients who develop brain metastases during the study will be allowed to continue treatment as assigned~* Not pregnant and not nursing~* ECOG performance status 0-2~* Calculated creatinine clearance \>= 30 mL/min~* Corrected serum calcium \>= 8.0 mg/dL (2.00 mmol/L) and \< 11.6 mg/dL (2.90 mmol/L) \* Corrected serum calcium should be calculated using standard institutional practices

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (zoledronic acid every 4 weeks) (Type: EXPERIMENTAL): Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
- Arm II (zoledronic acid every 12 weeks) (Type: EXPERIMENTAL): Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with symptomatic fibroids who desire future fertility and or who wish to maintain their uterus.~Exclusion Criteria:~* patients who have had previous myomectomy or previous pelvic surgery.~* patients who are severely anemic or who have significant medical conditions such as cardiac or pulmonary disease.~* patients who refuse to participate or give consent to the procedures. Patients with a known allergy to any of the study drugs.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Misoprostol + vasopressin, Vasopressin (Type: EXPERIMENTAL): Misoprostol 400ug given rectally one hour before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be H. pylori-positive patients at baseline (Visit 1)~2. Participants must be endoscopically confirmed to have scarred gastric ulcer or duodenal ulcer at baseline (Visit 1).~   However, if a history of ulcers is confirmed by the medical interview or previous medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has disappeared may be included in the study.~3. Outpatient (including inpatient for examination)~Exclusion Criteria:~1. Participants who have received H.pylori eradication treatment~2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer \[mucosal defect (with white coating including clot adherence) of 3 mm or larger in size\], duodenal ulcer \[mucosal defect (with white coating including clot adherence) of 3 mm or larger in size\], acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1).~   However, participants with gastric erosion or duodenal erosion may be included in the study.~3. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc)~4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric stenosis or large hemorrhage, etc)~5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~6. Participants with hepatic or renal impairment receiving treatment with colchicines~7. Participants who have a history of hypersensitivity or allergy to TAK-438 (including its excipients), PPIs, penicillin antibiotics, macrolide antibiotics, or antitrichomonal agents~8. Participants with infectious mononucleosis~9. Participants with an organic disease of the brain or spinal cord

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 20 mg BID (Type: EXPERIMENTAL): TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week
- Lansoprazole 30 mg BID (Type: EXPERIMENTAL): TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of the Different Concentrations of Oral Dextrose Solution Applying With Supportive Positions on Pain During Heel-Stick Sampling in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age (GA) at birth 33+0 - 37+0 weeks~* Admitted to NICU~* Planned the heel-stick sampling within the scope of the NSTs~* Parents are able to read, write and speak Turkish~Exclusion Criteria:~* With a postnatal age of 8 days or more~* Has contraindications for the administration of oral glucose (genetic, endocrine, metabolic diseases or neurological problems etc.)~* Has major congenital anomalies~* Has intubated or receiving a nCPAP~* Has received analgesics or sedatives for less than 24 hours before the procedure

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Supportive Positions + Oral Sterile Water (Type: PLACEBO_COMPARATOR): The enrolled premature infants will be administered 1ml of the sterile water a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of sterile water a second time.
- Supportive Positions + 10% Oral Dextrose (Type: ACTIVE_COMPARATOR): The enrolled premature infants will be administered 1ml of the 10% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 10% oral dextrose solution a second time.~(%10 oral dextrose solution: osmolarity= 550 mOsm/L, pH= 3.5-6.5, calorie=400 kcal/L)
- Supportive Positions + 20% Oral Dextrose (Type: ACTIVE_COMPARATOR): The enrolled premature infants will be administered 1ml of the 20% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 20% oral dextrose solution a second time.~(%20 oral dextrose solution: osmolarity= 1010 mOsm/L, pH= 3.2-6.5, calorie= 680 kcal/L)
- Supportive Positions + 30% Oral Dextrose (Type: ACTIVE_COMPARATOR): The enrolled premature infants will be administered 1ml of the 30% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 30% oral dextrose solution a second time.~(%30 oral dextrose solution: osmolarity= 1515 mOsm/L, pH= 3.2-6.5, calorie= 1020 kcal/L)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Managing Insulin With a Voice AI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 Diabetes~* Patients clinically indicated to be taking daily long-acting insulin~* Patients currently taking long-acting insulin but necessitating active dose adjustments~Exclusion Criteria:~* Patients who do not speak English~* Patients who do not own a smart phone~* Patients who do not have stable wireless internet connection at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Voice Assistant Device (Type: EXPERIMENTAL): Subjects have their insulin titrated by a voice assistant device for 8 weeks. The Voice Assistant Device software algorithm is used to provide daily insulin dose and titration instructions.
- Control (Type: ACTIVE_COMPARATOR): Subjects have their insulin titrated via standard of care for 8 weeks. The Voice Assistant Device is limited to providing a daily reminder to take medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Students in grades 9-12 at 14 public schools in Pennsylvania. This is a change from the originally anticipated 16 schools, as 2 were unable to continue participation. Anticipated enrollment numbers will be updated once the data are finalized.~HRSA funding for primarily rural school districts (only one is urban). PCORI funding for urban school districts.~Exclusion Criteria:~* Students whose parents complete the opt-out consent~* Students not enrolled in one of the participating schools~* Students not in grades 9-12~* Students with disabilities that are deemed unable to participate by the school district

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Targeted Screening Arm (Current Process) (Type: NO_INTERVENTION): Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
- Universal Screening Arm (Intervention) (Type: EXPERIMENTAL): Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores \>10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete